Health and economic consequences of sevelamer use for hyperphosphatemia in patients on hemodialysis

Value in Health

Volumn 8, Issue 5, 2005, Pages 549-561

  Huybrechts, Krista F ^a   Caro, J Jaime ^a,b   Wilson, David A ^c   O'Brien, Judith A ^a  

^a CARO RESEARCH INSTITUTE   (United States)

^b ROYAL VICTORIA HOSPITAL   (Canada)

^c GENZYME CORPORATION   (United States)

Author keywords

Cardiovascular events; Cost effectiveness; End stage renal disease; Phosphate binders

Indexed keywords

ACETIC ACID; CALCIUM ACETATE; CARBONIC ACID; PHOSPHATE; SEVELAMER; ACETIC ACID DERIVATIVE; CARDIOTONIC AGENT; EPOXIDE; POLYAMINE; POLYETHYLENE DERIVATIVE;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DRUG BINDING; DRUG COST; DRUG EFFICACY; DRUG SAFETY; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH ECONOMICS; HEART PROTECTION; HEMODIALYSIS; HUMAN; HYPERPHOSPHATEMIA; KIDNEY FAILURE; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; ADULT; AGED; BLOOD; CALCINOSIS; CARDIOMYOPATHY; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; COST BENEFIT ANALYSIS; DISORDERS OF MINERAL, ELECTROLYTE AND METAL METABOLISM; ECONOMICS; FEMALE; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; RENAL REPLACEMENT THERAPY; TIME; UNITED STATES;

ACETATES; ADULT; AGED; CALCINOSIS; CARDIOMYOPATHIES; CARDIOTONIC AGENTS; COST-BENEFIT ANALYSIS; DIRECT SERVICE COSTS; EPOXY COMPOUNDS; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PHOSPHATES; PHOSPHORUS METABOLISM DISORDERS; POLYAMINES; POLYETHYLENES; PROPORTIONAL HAZARDS MODELS; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS; REGRESSION ANALYSIS; RENAL DIALYSIS; TIME; UNITED STATES;

EID: 27744457024     PISSN: 10983015     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2005.00049.x     Document Type: Article

References (49)

1. Rakel RE, Bope ET, eds. Conn's Current Therapy 2001: Latest Approved Methods of Treatment for the Practicing Physician. Philadelphia, PA: W.B. Saunders Company, 2001.
2. U.S. Renal Data System, USRDS 2003 Annual Data Report. Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health. National Institute of Diabetes and Digestive and Kidney Diseases, 2003.
3. London GM, Guerin AP, Marchais SJ, et al. Cardiac and arterial interactions in end-stage renal disease. Kidney Int 1996;50:600-8.
4. Weintraub WS. Coronary artery calcium and cardiac events: is electron-beam tomography ready for prime time? Circulation 2003;197:2528-30.
5. Detrano RC, Wong ND, Doherty TM, et al. Coronary calcium does not accurately predict near-term future coronary events in high-risk adults. Circulation 1999;99:2633-8.
6. Raggi P, Callister TQ, Cooil B, et al. Identification of patients at increased risk of first unheralded acute myocardial infarction by electron-beam computed tomography. Circulation 2000;101:850-5.
7. Raggi P, Cooil B, Callister TQ. Use of electron beam tomography data to develop models for prediction of hard coronary events. Am Heart J 2001;141:375-82.
8. Wong ND, Hsu JC, Detrano RC, et al. Coronary artery calcium evaluation by electron beam computed tomography and its relation to new cardiovascular events. Am J Cardiol 2000;86:495-8.
9. Arad Y, Spadaro LA, Goodman K, et al. Prediction of coronary events with electron beam computed tomography. J Am Coll Cardiol 2000;36:1253-60.
10. Kondos GT, Hoff JA, Sevrukov A, et al. Electron-beam tomography coronary artery calcium and cardiac events: a 37-month follow-up of 5,635 initially asymptomatic low-to intermediate-risk adults. Circulation 2003;107:2571-6.
11. Pletcher MJ, Tice JA, Pignone M, Browner WS. Using the coronary artery calcium score to predict coronary heart disease events: a systematic review and meta-analysis. Arch Intern Med 2004;164: 1285-92.
12. Schoenhagen P, Tuzcu EM. Coronary artery calcification and end-stage renal disease: vascular biology and clinical implications. Cleve Clin J Med 2002;69(Suppl.3):S12-20.
13. McCullough PA, Soman S. Cardiovascular calcification in patients with chronic renal failure: are we on target with this risk factor? Kidney Int 2004;66(Suppl.90):S18-24.
14. Hsu CH. Are we mismanaging calcium and phosphate metabolism in renal failure? Am J Kidney Dis 1997;29:641-9.
15. Block GA. Prevalence and clinical consequences of elevated Ca x P product in hemodialysis patients. Clin Nephrol 2000;54:318-24.
16. Guérin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000;15:1014-21.
17. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342:1478-83.
18. London GM, Guérin AP, Marchais SJ, et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003;18:1731-40.
19. Physicians' Desk Reference (57th ed.). Montvale NJ: Medical Economics Company, Inc, 2003.
20. Chertow GM, Burke SK, Raggi P. Treat to Goal Working Group: sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62:245-52.
21. Raggi P, Bommer J, Chertow GM. Valvular calcification in hemodialysis patients randomized to calcium-based phosphorous binders or sevelamer. J Heart Valve Dis 2004;13:134-41.
22. Banks J, Carson JS, Nelson BL. Discrete-Event System Simulation. Englewood Cliffs, NJ: Prentice Hall, 1996.
23. Caro JJ. Pharmacoeconomic analysis using discrete event simulation. Pharmacoeconomics 2005;23: 323-32.
24. Agatston AS, Janowitz WR, Hildner FJ, et al. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990;15:827-32.
25. Kelton WD, Sadowski RP, Sadowski DA. Simulation with arena. Boston, MA: McGraw-Hill, 1998.
26. Burke SK, Dillon MA, Hemken DE, et al. Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients. Adv Ren Replace Ther 2003;10:133-45.
27. Juckett DA, Rosenberg B. Comparison of the Gompertz and Weibull functions as descriptors for human mortality distributions and their intersections. Mech Ageing Dev 1993;69:1-31.
28. Blacher J, Guérin AP, Pannier B, et al. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001; 38:938-42.
29. Huybrechts KF, Caro JJ, London GM. Modeling the implications of changes in vascular calcification in patients on hemodialysis. Kidney Int 2005;67:1-7.
30. Collett D. Modelling Survival Data in Medical Research. Boca Raton, FL: Chapman & Hall/CRC, 1994.
31. Massachusetts Office of Health Care Finance and Policy. 1998 Cost-to-charge Ratio for Massachusetts Hospitals. Boston, MA: Office of Health Care Finance and Policy, 1999.
32. California 1999 Discharge Data (Version A). Sacramento, Calif.: Office of Statewide Health Planning and Development, 1999.
33. Florida Hospital Patient Data File. Tallahassee, Fla.: Agency for Health Care Administration, State Center for Health Statistics, 1999.
34. Massachusetts Fiscal Year Acute Hospital Case Mix Data Base, Level III. Boston, Mass.: Massachusetts Division of Health Care Finance and Policy, 1999.
35. Maryland Inpatient Public Use File. Baltimore, Md.: St. Paul Computer Center, Inc, 1999.
36. Washington CHARS (Comprehensive Hospital Abstract Reporting System) Public Data File. Olympia, Wash.: Washington State Department of Health, Office of Hospital and Patient Data, 1999.
37. American Medical Association. Physicians' Current Procedural Terminology. Chicago, IL: American Medical Association, 2002.
38. 2002 National Physician Fee Schedule Payment Amount File. Centers for Medicare & Medicaid Services. Available from: http://www.cms.hhs.gov/ providers/pufdownload/carrpuf.asp. [Accessed November, 2001].
39. U.S. Department of Health and Human Services. Medicare and Medicaid Statistical Supplement, 2000. Health Care Finance Review. Baltimore, MD: HCFA Office of Strategic Planning, 2001.
40. Manton KG, Cornelius ES, Woodbury MA. Nursing home residents: a multivariate analysis of their medical, behavioral, psychosocial and service use characteristics. J Gerontol 1995;50A:M242-51.
41. MediMedia: Gelbe listed Pharmindex. Available from: http://www.pharmazie. com [Accessed November 2001].
42. Medical Economics. 2001 Drug Topics Red Book. Montvale, NJ: Medical Economics, 2001.
43. Winkelmayer WC, Weinstein MC, Mittleman MA, et al. Health economic evaluations: the special case of end-stage renal disease. Med Decis Making 2002;22:417-30.
44. Krumholz HM, Cohen BJ, Tsevat J, et al. Cost-effectiveness of a smoking cessation program after myocardial infarction. J Am Coll Cardiol 1993; 22:1697-702.
45. Mark DB, Hlatky MA, Califf RM, et al. Cost-effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995;332:1418-24.
46. Blacher J, Guérin AP, Pannier B, et al. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999;99:2434-9.
47. Janowitz WR. Coronary calcium does not accurately predict near-term future coronary events in high-risk adults [letter to the editor]. Circulation 2000;102:E20.
48. Caro JJ, Ishak KJ, Migliaccio-Walle K. Estimating survival for cost-effectiveness analyses: a case study in atherothrombosis. Value Health 2004;7: 627-35.
49. Collins AJ, St. Peter WL, Dalleska FW, et al. Hospitalization risks between Renagel phosphate binder treated and non-Renagel treated patients. Clin Nephrol 2000;54:334-41.